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SUMMARY 
 
Diabetes mellitus is a disorder characterised by hyperglycaemia and other 
metabolic derangements. Diagnosis of diabetes has evolved over the years, but 
has been based around blood glucose measurements. Glycated haemoglobin 
(HbA1c) has an established role in the monitoring of glycaemia control. More 
recently its use as a diagnostic test for diabetes has been advocated as well. 
Practical advantages include the fact that fasting is not required for specimen 
collection. However, there are issues surrounding its use, such as 
standardisation and coexistent haemoglobinopathies. The aim of this study was 
to compare HbA1c with fasting plasma glucose in the diagnosis of type 2 
diabetes and intermediate hyperglycaemia in obese patients, with a secondary 
aim to characterise the metabolic profile of patients identified with these criteria. 
This was a retrospective analysis, covering February 2010 and November 2011. 
 
It was hypothesised that there would be some differences in the number of 
subjects identified in each classification (FPG, HbA1c IEC and ADA criteria), as 
FPG and HbA1c measure different aspects of the metabolic profile and the 
HbA1c IEC and ADA criteria are different in the pre-diabetes and normal 
categories. It was hypothesised that there would be no significant differences in 
the metabolic profile of the subjects identified by each classification, as subjects 
were from the obesity clinic and it was anticipated that the metabolic profile within 
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each classifications would be similar. It was also hypothesised that the number of 
subjects in the IFG/pre-diabetes categories fulfilling the ATP III fasting glucose 
criteria would be different and there would be small differences in the subjects 
fulfilling each available ATP criteria identified by each classification in the 
IFG/pre-diabetes categories, due to the reasons above. 
 
Patients were identified from the NHS Tayside Specialist Weight Management 
Service. They were classified into three groups (normoglycaemia, IFG/pre-
diabetes, and diabetes) according to their fasting plasma glucose (FPG) and 
HbA1c. The International Expert Committee (IEC) and the American Diabetes 
Association (ADA) have different cut-off points for diagnosis of pre-diabetes; both 
classification criteria were applied in the current study. Metabolic data (insulin, 
triglyceride, cholesterol, uric acid, alanine aminotransferase, alkaline 
phosphatase, sex hormone-binding globulin and testosterone) were compared 
and the distribution of patients in the diabetes, IFG/pre-diabetes and 
normoglycaemic groups were analysed.  
 
102 subjects were classified as normoglycaemic, 13 were classified with IFG and 
5 were DM by FPG; 89 subjects were classified as normoglycaemic, 21 were 
classified with pre-diabetes and 7 were DM by HbA1c (IEC) and 69 subjects 
were classified as normoglycaemic, 41 were classified with pre-diabetes and 7 
were DM by HbA1c (ADA). 
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Significance was observed in the F-value of alkaline phosphatase in groups 
categorised by FPG (p <0.001); significant (p <0.001) F-values were found in 
triglyceride and alkaline phosphatase, in subjects identified by HbA1c (IEC 
standard) and additionally F-value in cholesterol ratio are found to be significant 
(p=0.027) in subjects identified by HbA1c (ADA standard), showing between-
groups and within-group variabilities. Normality was not assessed in these 
subjects and ROC curves showed highly significant differences (p <0.001) in 
triglyceride, alkaline phosphates and SHBG; significant difference (p<0.05) in 
alanine transferase in the HbA1c (IEC) categorisation. In subjects identified by 
HbA1c (ADA standard), the ROC curve of triglyceride level are found to be very 
highly significant (p<0.001), the ROC curve of in alkaline phosphatase and 
cholesterol ratio are found to be significant. The ROC curve of insulin was also 
shown to be significant (p<0.05).  
 
Data was separated into male and female subjects, normality was assessed. The 
data was found to be unevenly distributed, therefore ROC curves were used to 
assess the data. In male subjects identified by HbA1c (IEC standard) ROC 
curves of triglyceride, and alkaline phosphatase were highly significant (p<0.01). 
In addition, the ROC curve of alanine aminotransferase and uric acid was 
significant (p <0.01) and SHBG was very highly significant (p <0.001). In female 
subjects identified by HbA1c (ADA standard), the ROC curve of triglyceride level 
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were found to be highly significant (p <0.01); in male subjects identified by HbA1c 
(ADA standard), the ROC curves of triglyceride, cholesterol ratio and SHBG level 
were found to be significant (p <0.05), the ROC curve of alanine 
aminotransferase was found to be highly significant (p <0.01). The differences in 
the male groups demonstrated could be due to the small sample size in the 
IFG/pre-diabetes and diabetes group of subjects. 
 
Metabolic syndrome is a complex disorder associated with insulin resistance and 
an increased risk of diabetes. The Adult Treatment Panel (ATP III) criteria are 
widely applied in the diagnosis of the metabolic syndrome. Therefore, we also 
examined the number of patients identified by FPG and HbA1c that fulfilled those 
ATP III criteria that were measured in the current study. We found that 10 out of 
13 subjects (76.9%) met three out of five ATP III criteria using FPG; 8 out of 21 
subjects (38.1%) using IEC, and 14 out of 41 subjects (34.2%) using the ADA 
criteria in the pre-diabetes group. 
 
In conclusion, this research project compared HbA1c with fasting glucose in the 
diagnosis of type 2 diabetes and intermediate hyperglycaemia, in a specified 
cohort of patients. We identified 126 patients for inclusion into the study. 
Differences were observed according to the diagnostic categorisation of patients. 
Future recommendations include follow-up of these patients in order to observe 
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development of diabetes from the IFG/pre-diabetes group identified by each of 
the three classifications: FPG, HbA1c (IEC) and HbA1c (ADA).  
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CHAPTER 1 
INTRODUCTION 
 
Background: Diabetes mellitus (DM) is a group of metabolic disorders 
characterised by hyperglycaemia (American Diabetes Association, 2010). 
Diagnosis of DM has changed over the years (World Health Organisation, 2011). 
Initially, the diagnosis of DM was mainly based on glycosuria (Banting FG et al., 
1922). Thereafter, diagnosis and treatment of DM have largely been based 
around measurement of blood glucose concentrations. Another measure of 
glycaemia is the glycated haemoglobin (HbA1c); this is a ‘weighted average’ of 
blood glucose levels for the preceding 120 days (Rohlfing et al., 2000). It has 
been employed routinely in the monitoring of glycaemic control in diabetes 
management (Kilpatrick, 2004) since the late 1970s (Rohlfing et al., 2002). 
Before the introduction of HbA1c, assessing glycaemic control relied on other 
tests including 24-hour urine glucose excretions (Gabbay et al., 1977) and daily 
blood glucose profiles (Gonen et al., 1977), and fructosamine (Sebastian, 1999). 
A key advantage of HbA1c testing is that the patient does not have to fast 
(American Diabetes Association, 2010).   
 
In 1997, a working party of the American Diabetes Association (ADA) suggested 
that HbA1c could be used for the diagnosis of diabetes (McCance et al., 1997). 
However, in Europe, and elsewhere, it was not recommended as a diagnostic 
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test at the time, for a number of reasons. For example, it was difficult to set a 
standard cut-off point, and assays for HbA1c were not widely available in 
developing countries (World Health Organisation, 1999). Since then, the World 
Health Organisation (WHO) has held an expert consultation, which reported 
following a systematic review of HbA1c as a diagnostic test for DM (World Health 
Organisation, 2011). The consultation concluded that HbA1c can be used as a 
diagnostic test for diabetes, provided ‘stringent quality assurance tests are in 
place and assays are standardised to criteria aligned to the international 
reference values’ (World Health Organisation, 2011). HbA1c of 6.5% is 
recommended as the cut-off point for diagnosing diabetes (World Health 
Organisation, 2011). In January 2011 Diabetes UK endorsed the use of the 
HbA1c test to diagnose diabetes (John and Hillson, 2011), providing the patients 
are suitable and the quality control of the tests are met. Studies are required to 
ascertain the impact of changing from traditional means of diagnosing diabetes 
(fasting glucose, and/or oral glucose tolerance testing), to HbA1c.  
 
Aims and Objectives: The aim of this project is to compare HbA1c with fasting 
glucose in the diagnosis of type 2 diabetes and intermediate hyperglycaemia 
(impaired fasting glycaemia), in our specified cohort of patients.  
 
The objective of the project is to evaluate metabolic data collected from the NHS 
Tayside specialist weight management service. Metabolic measurements 
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including glucose, insulin, HbA1c, lipids, androgen status and renal function have 
been performed. The potential impact of using HbA1c versus fasting glucose will 
be assessed. HbA1c and body mass index (BMI) data will be compared in order 
to assess if the relationship between HbA1c and fasting glucose in the diagnosis 
of DM varies according to obesity. In addition, groups diagnosed with diabetes 
and IFG using each method will be compared with respect to other measures, 
e.g. lipids; number of patients in the intermediate glycaemia group identified by 
each method will be compared with the ATP III criteria. 
 
It was hypothesised that there would be some differences in the number of 
subjects identified in each classification (FPG, HbA1c IEC and ADA criteria), as 
FPG and HbA1c measure different aspects of the metabolic profile, and the 
HbA1c IEC and ADA criteria are different in the pre-diabetes and normal 
categories. It was hypothesised that there would be no significant differences in 
the metabolic profile of the subjects identified by each classification, as subjects 
were from the obesity clinic and it was anticipated that the metabolic profile within 
each classifications are similar. It was also hypothesised that the number of 
subjects in the IFG/pre-diabetes categories fulfilling the ATP III fasting glucose 
criteria would be different and there would be small differences in the subjects 
fulfilling each available ATP criteria identified by each classification in the 
IFG/pre-diabetes categories, due to the reasons above. 
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CHAPTER 2 
LITERATURE REVIEW 
 
2.1 HISTORY OF DIABETES 
 
DM encompasses a group of metabolic disorders characterised by 
hyperglycemia (American Diabetes Association, 2010).  It may occur as a result 
of defective insulin secretion, or utilisation of both insulin and fuel (insulin 
resistance). Diabetes, named after the Greek Aretaeus around AD100, is a very 
well documented disease. It was first described as ‘a melting down of the flesh 
and limbs into the urine’ (Aretaeus, N.D.). Aretaeus also identified the classical 
symptoms of thirst, polyuria and dehydration which are very common today 
(Aretaeus, N.D.). Hindu physicians, from more than 1500 years ago, described 
the urine as sweet-tasting (Wilding 1998), and other physicians such as Chen 
Chuan in the 7th century and Thomas Willis in the 17th century agreed with this 
(Sebastian, 1999).  
 
A number of landmark discoveries influenced the way in which diabetes has 
been understood. Mering and Minkowski in 1889 discovered the urine of their 
pancreatectomised dogs attracted flies because it was sweet-tasting, and 
therefore they concluded that the pancreas is essential for the control of blood 
sugar concentration. In 1921 Banting and Best successfully purified insulin into 
an injectable form. This extract was tested on diabetic dogs, which demonstrated 
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a marked reduction in blood and urinary sugar levels (Banting FG et al., 1922). 
As a direct result of these early discoveries of diabetes the condition has been 
essentially viewed as a ‘glucocentric’ disorder which is primarily associated with 
abnormal glucose metabolism (McGarry, 1992). However, McGarry (1992) 
challenged this notion. He believed that abnormal fat metabolism plays an 
important role, at least partially, in the pathogenesis of DM.  
 
2.2 DIAGNOSTIC CRITERIA 
 
Hyperglycaemia is a defining feature of DM (World Health Organisation, 1999), 
and the advent of blood glucose measurement has meant that fasting glucose 
tests which demonstrate hyperglycaemia can be used to diagnose diabetes 
(McCance et al., 1997). 
 
The diagnosis and treatment of DM have mainly been focused on glycaemic 
control because of the aforementioned. In the clinical setting, urinary glucose 
dipstick testing has been used to screen for diabetes. It is a convenient way to 
identify those with DM as it is a non-invasive procedure that yields instant at-the-
bedside results. A positive result (glycosuria) will lead the medical practitioner to 
request one of the following blood tests: fasting plasma glucose, random plasma 
glucose test or an oral glucose tolerance test (OGTT).  
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2.2.1 Guidelines and Recommendations 
 
Several guidelines regarding the diagnosis and treatment of DM have been 
published by the WHO since 1965 (World Health Organisation, 2006). The 1985 
WHO report which defined the diagnostic criteria of DM was used for over a 
decade. It included symptoms such as increased thirst, and urine volume, 
unexpected weight loss, drowsiness, coma and high levels of glycosuria (WHO, 
1985). Venous blood test results were divided into three groups: ‘diabetes 
mellitus likely’- venous plasma glucose ≥, 11.1 mmol/l (>200 mg/dl); ‘diabetes 
mellitus uncertain’- venous plasma glucose 5.5-<11.1 mmol/l (100-<200 mg/dl); 
and ‘diabetes unlikely’- venous plasma glucose <5.5 mmol/l (< 100 mg/dl) (WHO, 
1985). If ‘diabetes mellitus is likely’ a solitary result would establish the diagnosis 
regardless of whether symptoms are present or not (WHO, 1985). If the value 
lies in the ‘uncertain’ range, an oral glucose tolerance test (OGTT) is indicated. 
This involves measuring blood glucose before and 2 hours after the oral 
ingestion of a glucose load containing the equivalent to 75g anhydrous glucose 
dissolved in water (Diabetes UK, 2000). In 1997 the WHO responded to the 
recommendations made by the American Diabetes Association (ADA) in 1997 by 
suggested that the diagnosis of diabetes should not be based on a single 
abnormal glucose value and rather, other factors (e.g. ethnicity, family, age, 
adiposity and concomitant disorders) should also be considered (World Health 
Organisation, 1999). The WHO has since advised that the diagnostic value of the 
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fasting plasma glucose (FPG) should be lowered from 140mg/dl (7.8mmol/l) to 
126mg/dl (7.0mmol/l), and in whole blood from 120 mg/dl (6.7 mmol/l) to 
110mg/dl (6.1 mmol/l) (World Health Organisation, 1999), concurring with the 
ADA’s recommendation. This new practice has been adopted in the UK following 
extensive research into complications relating to the disease (Diabetes UK, 
2000). 
 
The diagnostic criteria suggested by Diabetes UK in 2000 and the International 
Expert Committee IEC, in 1997 (Mayfield, 1998) are in keeping with the WHO 
1999 report (World Health Organisation, 1999). These criteria include: 
 
1. Diabetes symptoms (polyuria, polydipsia and unexplained weight loss) 
plus a random venous plasma glucose concentration ≥11.1 mmol/l or a 
FPG ≥7.0 mmol/l  or two-hour plasma glucose concentration ≥11.1 mmol/l 
after a OGTT (Diabetes UK, 2000). 
 
2. A definitive diagnosis should not be made in the asymptomatic patient  
following a single abnormal glucose test and a confirmatory plasma 
venous test on a separate occasion should be done (Diabetes UK, 2000). 
This can be in the forms of a FPG, random sample or OGTT (Diabetes 
UK, 2000). 
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Impaired glucose tolerance reflects impaired glucose regulation and is defined as 
a FPG <7.0 mmol/l and a glucose of 7.8-11.0 mmol/l 2 hours after the oral 
glucose has been administered. Impaired fasting glycaemia (IFG) has now been 
introduced as a comparable state of intermediate glycaemia, in order to classify 
individuals who have fasting glucose concentrations above the normal range but 
below the concentration that is diagnostic of diabetes (6.1-6.9 mmol/l).  
 
Diabetes UK recommends that a diagnosis is confirmed by a glucose 
measurement performed in an accredited laboratory on a venous plasma sample 
although the WHO suggests whole blood is acceptable as well (Diabetes UK, 
2000). There should be less need for using the OGTT (Diabetes UK, 2000), 
although it still remains helpful in situations where fasting glucose might not be 
accurate, such as in the elderly and in some ethnic minority groups (Diabetes 
UK, 2000). 
 
The Scottish Intercollegiate Guidelines Network guideline (SIGN 116) on the 
management of diabetes follows the same principles of diagnosis as 
recommended by Diabetes UK. The OGTT is only used to establish diagnostic 
status if the random glucose value lies in an uncertain range and the fasting 
glucose is below the diagnostic value (Scottish Intercollegiate Guidelines 
Network, March 2010). SIGN 116 also recommended the changes on FPG and 
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whole blood as previously suggested by the WHO (1999) and Diabetes UK 
(2000). 
 
2.2.2 HbA1c 
 
HbA1c is the percentage of adult haemoglobin (Hb) that is glycated (Nathan et 
al., 2007). The glycation process involves the binding of carbohydrates non-
enzymatically to proteins such as Hb (Kilpatrick, 2000). HbA1 refers to charge-
separated haemoglobins of normal adult HbA0 (Kilpatrick, 2000). Glycated Hb is 
a generic term for Hb bound irreversibly, in ketoamine form, to glucose (Wong 
WH, 1999). This includes HbA1, HbA1c and total glycated haemoglobin. HbA1 in 
addition may be further sub-classified as HbA1a1, HbA1a2, HbA1b and HbA1c 
(Kilpatrick, 2000). Total glycated Hb also includes the glycated Hb variants. 
HbA1c is the major sub-fraction of the glycated normal Hb (Wong, 1999). 
Carbohydrate, of which glucose is the major fraction, binds to Hb to form HbA1c. 
HbA1c was first identified as a minor fraction of normal adult Hb by ion exchange 
chromatography nearly 4 decades ago (Kilpatrick, 2000). 
 
HbA1c represents the ‘weighted average’ of blood glucose levels over the 
preceding 120 days from when the test is taken (Rohlfing et al., 2002). It has 
been routinely used in the management of diabetes (Kilpatrick, 2004) since the 
late 1970s (Rohlfing et al., 2002). Previously, monitoring long-term glycaemic 
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control relied on tests such as ‘24 hour urinary collections’ and ‘daily blood 
glucose profiles’ (Kilpatrick, 2004) and fructosamine (Kilpatrick et al., 1996). In 
comparison, HbA1c is a more reliable measure of glucose control, no fasting is 
required and only requires a single venous blood sample (ADA, 2010). HbA1c is 
a well-established and documented test for monitoring diabetes but its 
importance and potential use as a primary diagnostic tool is yet to be determined. 
 
The big change in 1997 was the recommendations made by the ADA: 
(a) Change ‘fasting glucose’ criterion from 7.8 mmol/L to 7.0 mmol/L.  
(b) Abandon the OGTT and diagnose diabetes by FPG alone. 
 
Some experts believed that HbA1c could be used for the diagnosis of diabetes 
but there were concerns due to limitations of the test (Mayfield, 1998): HbA1c is 
a dynamic test affected by age, race, pregnancy, different laboratory standards 
and co-morbid disease such as haemoglobinopathies and renal failure (Nielsen 
et al., 2004). Haemoglobinopathies, which are particularly prevalent in Africa, the 
Mediterranean and South East Asia, iron deficiency and haemolytic anaemia 
(Kilpatrick et al., 2009, Coban et al., 2004) can affect HbA1c levels. Renal failure 
can affect HbA1c levels via haemolysis and iron deficiency and also through the 
formation of carbamylated haemoglobin (Kilpatrick et al., 2009). HIV patients who 
are taking anti-viral drugs can have 1% lower HbA1c (Kilpatrick et al., 2009). The 
IEC have suggested that ageing affects HbA1c with a 0.4% increase in 70 year 
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olds compared to 40 year olds with the same glucose tolerance.  In addition, a 
0.4% HbA1c increase is also seen in Afro-Caribbeans comparing to Europids 
(Kilpatrick et al., 2009). HbA1c levels are significantly decreased in pregnancy, 
compared to age-matched non-pregnant women. This is reflected by a study that 
identified varying ranges of HbA1c in non-pregnant women (4.7-6.3%), in early 
pregnancy (4.5-5.7%) and in late pregnancy (4.4-5.6%) (Nielsen et al., 2004, 
Kilpatrick et al., 1998).  
 
Although a HbA1c value of 6.5% (48 mmol/mol) is recommended as the cut-off 
point for diagnosing diabetes, a value of less than 6.5% does not exclude 
diabetes (World Health Organisation, 2011b). The WHO also concluded that 
there was insufficient evidence to make any formal recommendations on the 
interpretation of HbA1c levels below 6.5% (World Health Organisation, 2011b). 
Further work by the WHO concluded that HbA1c can be used as a diagnostic 
test, provided ‘stringent quality assurance tests are in place and assays are 
standardised to criteria aligned to the international reference values’ (World 
Health Organisation, 2011). 
 
2.2.3 Pros and Cons of Diagnostic Tests for DM 
 
Glucose as a diagnostic tool directly measures the glucose molecules which are 
thought to be the direct cause of many of the complications of DM. Complications 
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result from the formation of reactive free radicals generated by hyperglycaemia 
(Brownlee, 2005). Epidemiological studies of diabetic retinopathy have identified 
a threshold glucose level at which retinopathy becomes apparent (American 
Diabetes Association, 1997). A direct relationship exists between the degree of 
plasma glucose control and the risk of retinal, renal and neurologic complications 
(UK Prospective Diabetes Study (UKPDS) Group, 1998). 
 
Some studies have shown that higher glucose concentrations are linked to a 
poorer prognostic outcome (Sasaki, 1981). Therefore the glucose measurement 
is a useful tool to predict the consequences of DM. Glucose measurement is not 
affected by non-glycaemic factors (e.g. haemoglobinopathies) and it 
demonstrates fewer inter-laboratory differences in the UK than HbA1c. In 
addition glucose measurements are more comparable from laboratories around 
the world in comparison to HbA1c results (Kilpatrick et al., 2009). However, 
glucose testing as a solitary measurement requires the patient to fast for at least 
8 hours prior to sampling, with no calorie intake (American Diabetes Association, 
1997). This can be a challenge for some patients. 
 
Diurnal variation of FPG may manifest as a higher FPG in the morning and a 
lower FPG in the afternoon.  This means the testing must be standardised for 
quality control of results and all patients should be seen at the same time on 
successive occasions (Troisi et al., 2000).  Plasma glucose samples need to be 
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analysed promptly as glycolysis can cause the concentration in ex-vivo blood to 
decrease. Fluoride can help maintain long-term glucose stability and is usually 
added to sampling bottles to preserve it. However, the greatest decline in 
glucose concentration occurs in the first hour from venepuncture (Chan et al., 
1989). 
 
Oral glucose tolerance testing (OGTT) is required when assessing an 
individual for impaired glucose tolerance. The OGTT formally assesses whether 
individuals have impaired glucose tolerance. However, it is inconvenient, has 
poor reproducibility (Ganda et al., 1978), is affected by variations in plasma 
glucose concentrations and by ambient temperatures (Moses et al., 1997). 
Glucose measurements represent the blood sugar concentrations at two points in 
time (0 minutes and 120 minutes). But individual variability may render these 
results less reliable than HbA1c and oral glucose tolerance test such as those 
who have undergone gastric surgery (Kilpatrick et al., 2009). 
 
HbA1c is a well-established DM monitoring tool for DM (Mayfield, 1998). HbA1c 
has been found useful in the identification of patients at risk of retinopathy and 
nephropathy (McCance et al., 1994). In 2009, the ADA started using HbA1c as a 
diagnostic tool for DM. Recently, the IEC extensively reviewed all the 
epidemiological evidence associated with HbA1c and found that it provides a 
reliable measurement of chronic glycaemia and suggested it may be a better 
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means of diagnosing DM (Fonseca et al., 2009). Diabetes complications were 
examined: HbA1c is just as predictive of retinopathy as glucose measurement 
(The International Expert Committee, 2009). As discussed, HbA1c represents the 
percentage of adult haemoglobin which is glycated (Nathan et al., 2007) and 
haemorrhage and blood transfusion can confound results (The International 
Expert Committee, 2009).  
 
HbA1c has its strengths. As mentioned, unlike the OGTT and FPG, no prior 
preparation or fasting is required. (American Diabetes Association, 2010). While 
collecting a blood sample for HbA1c, other biochemistry tests can be 
concurrently collected. HbA1c is collected and stored in tubes with 
ethylenediaminetetraacetic acid (EDTA), which acts as an anticoagulant. In 
summary, the HbA1c test is a clinically convenient test with less pre-analytical 
instability (The International Expert Committee, 2009). 
 
 
Other tests are available which may be useful in specific circumstances. 
Fructosamine reflects glycaemic control over the preceding 1-3 weeks 
(Kilpatrick et al., 1996) and it is used in pregnancy and in those suffering with 
haemoglobinopathies to assess control over a shorter period than HbA1c 
(Longsmore M, 2008). Older studies in the past had also used Mean Amplitude 
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of Glycaemic Excursions (MAGE) as an objective system to quantify glycaemic 
instability (Service et al., 1970).  
 
The limitations and uncertainties linked to the use of HbA1C as a single 
diagnostic test have been enough to defer its adoption in the United Kingdom 
(UK) to diagnose diabetes. In January 2011 Diabetes UK endorsed the use of the 
HbA1c test to diagnose diabetes (John and Hillson, 2011) with several 
qualifications/assumptions: that the patients are suitable, that staff are trained 
and that the method can demonstrate ‘internal quality control and external quality 
assessment performance that matches a laboratory method’ (World Health 
Organisation, 2011b). Most, but not all, patients are suitable for the test; 
however, as HbA1c reflects the chronic glycaemic state it is not suitable in 
situations where blood sugar concentrations have risen rapidly (John and Hillson, 
2011). For example symptomatic children and young people, those with a short 
duration of symptoms, acutely ill patients with a high risk of diabetes, pancreatic 
pathologies and those taking medications that may stimulate a rapid rise in 
glucose (e.g. corticosteroids) (John and Hillson, 2011) are all deemed unsuitable.  
 
 
HbA1c is a robust tool that reflects chronic glycaemia. There are strong 
correlations between HbA1c and retinopathy (The International Expert 
Committee, 2009), and it is at least as predictive of retinopathy as glucose-based 
tests (Kilpatrick et al., 2009). There is a lower within-person variability than 
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glucose. In the past, it was considered that there was lack of standardisation and 
normal ranges, therefore it was not used as a diagnostic tool (Mayfield, 1998). 
However, with a new reference method and standardisation led by IFCC 
(Kilpatrick et al., 2009) to calibrate HbA1c instruments, these issues are being 
addressed (The International Expert Committee, 2009). 
 
2.3 OBESITY AND DIABETES 
 
 
Associations has been made between obesity and diabetes for more than 1500 
years by Ayurvedic (Hindu) physicians, and it has been described as ‘a 
syndrome affecting older overweight patients who passed large volumes of 
sweet-tasting urine’ (Wilding J, 1998). In modern days, obesity plays a major role 
in 80% of type 2 diabetes, which remains the most important problem in diabetes 
management world-wide (Wilding J, 1998). 
 
Studies have confirmed that the risk of developing type 2 diabetes rises 
progressively with increased BMI and waist circumference (Chan et al., 1994). In 
a prospective cohort study, it has been demonstrated that weight gain in 
adulthood increases the risk of DM significantly, while weight loss can reduce the 
risk of DM (Colditz et al., 1995). The distribution of adipose tissue plays a role in 
the susceptibility to type 2 diabetes (Vague, 1956). Central obesity (android 
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obesity or ‘apple-shaped’) (Vague, 1956) is recognised as carrying an increased 
risk of metabolic syndrome, glucose intolerance and diabetes (Reaven, 1988, 
Després et al., 2008).  
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CHAPTER 3 
SUBJECTS AND METHODS 
 
This chapter details the subjects and methods used in this study. It outlines the 
selection of subjects and the methods used to compare the use of glycated 
haemoglobin (HbA1c) and fasting glucose measurements in the diagnosis of type 
2 diabetes and intermediate categories of hyperglycaemia (e.g. impaired fasting 
glycaemia).  
 
3.1 SUBJECTS 
 
The dataset for this study was assembled in the following way. First, patients 
were identified from the Tayside Specialist Weight Management Service 
database, having attended between February 2010 and November 2011 as new 
referrals. Subjects were included if either of the following criteria were met:  
(i) Body mass index (BMI) ≥40 kg/m2, irrespective of co-morbidity, or  
(ii) ≥35 kg/m2, with at least one relevant co-morbidity (e.g. cardiovascular 
disease, hypertension, hypercholesterolaemia). Their biochemical results 
were stored in the biochemistry database by the NHS Tayside Department of 
Biochemical Medicine. These results included fasting glucose, insulin, lipids, 
liver function tests, uric acid and androgen status.  
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In those cases where the BMI information had not been recorded on the request 
form, this information was extracted from other sources (clinic letters from dietetic 
and medical records). Clinical information i.e. whether the patients already have 
been diagnosed with diabetes, was established using information from 
biochemistry and dietetic sources.  
 
Approval by the University of Dundee Caldicott Guardian was sought and gained 
before data collection commenced.  
 
The subjects were given study numbers thereby ensuring the anonymity of the 
patients involved in this study. The dataset was stored on a secure hard drive to 
which only the researcher had access. 
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FPG samples 
n=120 
 
HbA1c sample n=117 
Missing FPG samples=6 
Missing HbA1c samples =9 
 
Enrolment n=212 
Final Sample Size 
n=126 
Excluded (n=86) 
• Non fasting 
samples n=27 
• Existing DM 
diagnosis n=59 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: Console flow diagram  
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3.2 METHODS 
 
The initial stage of the project involved data collection. A spreadsheet was 
constructed. Patients were identified from their first visit to the weight 
management service and the biochemical (metabolic) results of fasting venous 
plasma blood samples were accessed. These baseline metabolic profiles are 
routinely performed on every patient attending the weight management service 
for the first time. 
 
The BMI corresponding to the date of the blood sample was not always available 
from the request, and where necessary this was collected separately. Clinic 
notes from medical records, clinical letters stored by the dietetic department and 
a dietetic database were all accessed. These sources were also used to 
establish the diabetic status of patients. BMI data recording within 4 weeks from 
the date of the metabolic profile taken were included in the study. 
 
The metabolic profiles and BMI data were recorded onto a single spreadsheet. 
Patients were excluded from the dataset for the following reasons:  
1. There was a pre-existing diagnosis of diabetes mellitus. 
2. The venous samples of the metabolic profile were not fasting samples.  
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The metabolic profiles of patients with pre-existing diabetes may have been 
affected by their treatment. It would not have been possible to obtain data for 
fasting glucose from the non-fasting samples. 
 
The small numbers are partly explained by the difficulties encountered in the 
practical execution of this project. It was planned to be a prospective study, with 
data collection coinciding with sample collection. Sticky labels were made by the 
project supervisor, with the intention of collecting BMI data at the time of 
venepuncture. However, the use of these labels was poorly adhered to, and the 
BMIs of the patients were not input into the database. This necessitated 
retrospective collection of BMI data from several sources, including an electronic 
document store, a dietician’s database, clinic letters and case-notes. An 
additional issue was that the proportion of patients with prior DM was larger than 
anticipated, therefore requiring exclusion and resulting in smaller numbers. The 
small sample size means there is a possibility that these results are unreliable. 
 
The finalised group of subjects were categorised into diabetes, intermediate 
fasting glucose/pre-diabetes, and normal fasting glucose/normal HbA1c, 
according to three separate sets of criteria:  
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(i) Fasting glucose criteria as recommended by the World Health Organisation: 
• DM: ≥7.0mmol/L 
 
• IFG: 6.1-6.9 mmol/L 
• Normal: ≤6.0 mmol/L 
 
(ii) Glycated haemoglobin as recommended by the American Diabetic 
Association (ADA): 
• DM: ≥6.5%  
• Pre-diabetes: 5.7-6.4 % 
• Normal: ≤5.6 % 
 
(iii) Glycated haemoglobin as recommended by an International Expert 
Committee convened in 2008: 
• DM: ≥6.5%  
• Pre-diabetes: 6.0-6.4% 
• Normal: ≤5.9 % 
 
Body mass index was calculated from the patients’ weight (in kilograms) divided 
by their height (in meters) squared. These measurements were taken on the date 
of the clinic. 
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Venous blood was collected into Vacutainer tubes (Becton Dickinson, Cowley, 
UK) and delivered to the laboratory for testing. Glucose, glycated haemoglobin 
(HbA1c), insulin, triglyceride, cholesterol, uric acid, alanine aminotransferase 
(ALT), alkaline phosphatase, sex hormone-binding globulin (SHBG) and 
testosterone were measured. All the metabolic profiles were done according to 
the routine protocol weight management clinic. 
 
Glucose, cholesterol, triglycerides, uric acid, ALT and alkaline phosphatase were 
measured on a Cobas Integra 700 analyser (Roche Diagnostics, West Sussex, 
UK). HbA1c was measured using a Menarini Biomen HA 8140 analyser 
(Menarini Ltd, Berkshire, UK). Insulin and SHBG were measured by 
immunometric assay on a DPC Immulite analyser (Diagnostic Products 
Corporation, California, USA).  
 
Data analysis was performed using IBM software package for statistical analysis 
(SPSS) 19 (International Business Machines Corporation, New York, USA). 
Descriptive statistics on baseline data (eg sex, age, BMI and metabolic profiles) 
were established.  The F statistics of analysis of normal variance (ANOVA) was 
used to compare the metabolic profiles in the groups (diabetes, impaired fasting 
glycaemia/pre-diabetes, and normal fasting glucose/normal HbA1c) identified 
with the three different sets of criteria outlined above. This compared the in-
between group (DM/IFG/normal) and within group (DM/IFG/normal) variance in 
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the metabolic profile identified by each group (ie FPG/HbA1c (IEC)/HbA1c (ADA) 
standardisation. Insulin, triglyceride, cholesterol ratio, uric acid, ALT, alkaline 
phosphatase, sex hormone binding globulin (SHBG) and testosterone were 
compared. ROC curve was also used to compare the metabolic profiles in the 
groups. Normality for the dataset was not accessed. 
 
These data were re-analysed, separating female and male subjects, using a 
statistical package, PSPP (GNU project, 2014). Q-Q (quantile-quantile) plots 
were used to assess normality of the data. As the Q-Q plots demonstrated the 
data not to be normally distributed, ROC curves were used to assess the 
metabolic data as a non-parametric test.   
 
The Adult Treatment Panel III (ATP III) of the National Cholesterol Education 
Program established criteria for the diagnosis of metabolic syndrome (Expert 
Panel on Detection Evaluation and Treatment of High Blood Cholesterol in 
Adults, 2001). This recognised the importance of insulin resistance, its 
consequences and the associated risk of cardiovascular disease. The ATP III 
criteria for diagnosing the metabolic syndrome are as follows (National Heart and 
Lung and Blood Institue, 2002):  
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• Abdominal obesity  
o Men: waist circumference >40 inches (102cm) 
o Women: waist circumference >35 inches (89cm) 
• Fasting glucose ≥110 to < 126mg/dL (≥6.1 to ≤7.0 mmol/L) 
• Blood pressure ≥ 130/80mmHg 
• Triglycerides ≥ 150mg/dl (1.7 mmol/L) 
• HDL Cholesterol 
o Men: <40mg/dl (1.04mmol/L) 
o Women: <50mg/dL (1.3 mmol/L) 
 
Three or more of these five criteria met in an individual indicates metabolic 
syndrome. 
 
The assembled dataset contained fasting glucose, triglyceride and HDL 
cholesterol concentrations. Waist circumference data were not available. Every 
patient in this study had a BMI of at least 35kg/m2; data from Lean et al indicates 
that nearly everyone with BMI in this range meets the ATP III waist 
circumference criterion therefore it was therefore assumed that the ATP III waist 
circumference criterion was met in each case (Lean et al., 1995). Blood pressure 
was not available. Patients were categorised into diabetic/prediabetic/normal 
groups as described earlier, using the three separate sets of diagnostic criteria 
outlined above. The number of ATP criteria met in the different groups was 
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recorded, and the number of patients who met the ATP III criteria for metabolic 
syndrome in each group was also recorded.  
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CHAPTER 4 
RESULTS 
 
4.1 Baseline Data 
 
212 patients were included in the study. Samples excluded were: non-fasting 
samples (27) and samples from patients with existing diagnosis of diabetes (59), 
resulting in a final sample size of 126 patients. The female to male ratio was 
99:27, with 120 fasting glucose samples and 117 HbA1c samples available for 
this study. The baseline data for the patients in the study are as follows (mean ± 
SD): age 43.91 ± 11.66 years, BMI 48.27 ± 7.97 kg/m2, fasting glucose 5.42 ± 
0.86 mmol/l and HbA1c 5.65 ± 0.57%.  
 
The number of patients, age, sex and BMI classified by FPG, HbA1c (IEC 
standard) and HbA1c (ADA standard) are shown in table 1.  
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Table 1: Patient's demographics in categories classified by fasting glucose, HbA1c IEC 
and ADA criteria: patients' mean age, sex (male to female ratios) and mean BMI 
  
Fasting glucose 
 
HbA1c (IEC) 
 
HbA1c (ADA) 
 
Diabetes 
n 
mean age ± 
(SD) 
male:female 
mean BMI ± 
(SD)   
Mean FPG  ± 
(SD)  
 
 
 
n=5 
    47.20 Yrs ±  
(16.45)   
1:4 
48.69 kg/m2± 
(7.75) 
8.28± (1.29) 
       
 
 
n=7 
  44.29 Yrs ± 
(10.80)  
0:7 
50.09 kg/m2± 
(7.23) 
7.2± (1.87)      
 
 
n=7 
44.29 Yrs ± 
(10.80)  
0:7 
50.09 kg/m2± 
(7.23)  
7.2± (1.87)      
 
IFG/pre-
diabetes 
 n 
mean age ± 
(SD) 
male:female 
mean BMI ± 
(SD)  
Mean FPG  ± 
(SD)  
  
 
 
 
 
n=13 
44.30 Yrs ±  
(7.81)  
1:12 
50.17 kg/m2± 
(8.69) 
6.37± 
 (0.23) 
 
 
 
 
n=21 
45.80 Yrs ±  
(9.85) 
4:17 
48.09 kg/m2± 
(7.04) 
5.58 ±  
(0.69) 
  
 
 
n=41 
46.78 Yrs ± 
(10.90)  
9:32 
47.58 kg/m2 ± 
(6.90) 
5.6±  
(0.68) 
 
Normal 
n 
mean age ± 
(SD) 
male:female 
mean BMI ± 
(SD) 
Mean FPG  ± 
(SD)  
 
 
 
n=102 
43.28 Yrs ±  
(11.91)  
23:79 
47.70kg/m2±  
(7.88) 
5.16±  
(0.46) 
 
 
 
n=89 
42.92 Yrs ± 
(12.23)  
20:69 
48.13 kg/m2± 
(8.21) 
5.23±  
(0.61) 
 
 
n=69 
41.51 Yrs ± 
(12.00)  
15:54 
48.45kg/m2 ± 
(8.58) 
5.11±  
(0.54) 
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The mean age of patients identified by all the methods was in the fifth decade of 
their lives. Male individuals were under-represented across the groups (see 
tables 1), reflecting referral patterns from primary to secondary (specialist) care. 
The mean BMI of the patients in all three groups was above 40 kg/m2, indicating 
that all patients had class III obesity in this study.  
 
Fewer people were identified as having either diabetes or IFG when FPG criteria 
were applied, compared with HbA1c criteria (either IEC or ADA); correspondingly 
more were identified as normal (See table 2). Application of HbA1c ADA criteria 
predictably identified more subjects as having pre-diabetes than application of 
HbA1c IEC criteria; it has a lower cut-off (5.7% compared with 6.0%). 
 
 
Table 2: Descriptive Statistic of the Percentages of Patients Classified into Diabetes, 
IFG/Pre-Diabetes and Normal Groups Using Different Classifications (FPG/ HbA1c IEC’s 
and ADA’s HbA1c Criteria) 
 Normal IFG DM 
FPG 102 (85%) 13 (10.8%) 5 (4.2%) 
HbA1c (IEC) 89 (76.1%) 21 (17.9%) 7 (6.0%) 
HbA1c (ADA) 69 (59.0%) 41 (35.0%) 7 (6.0%) 
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Table 3: Number of patients co-responding between each group (Normal, Pre-DM/IFG 
and DM) by HbA1c (IEC and ADA) comparing to FPG categorisations 
  IEC   ADA  
 
Normal Pre-DM DM Normal Pre-DM DM 
FPG Categories       
Normal 80/102 14/102 3/102 64/102 30/102 3/102 
IFG 7/13 4/13 1/13 4/13 7/13 1/13 
Diabetes 1/5 1/5 3/5 0/5 2/5    3/5 
 
The number of subjects with normal HbA1c, identified by the IEC criteria, 
correlated better with the number of normal glycaemia subjects diagnosed by 
FPG, compared with using the ADA criteria. More subjects in the ADA category 
have been identified as pre-diabetes (see tables 1 and 2). Three subjects 
identified with normal glycaemia in the FPG group were classified as diabetes 
with their HbA1c level. This finding was supported by both IEC and ADA criteria.  
 
A larger number of subjects were identified with pre-diabetes by both IEC (n=21; 
17.9%) and ADA (n=41; 35%) categorisations (see table 2). In the FPG category 
this correlates with 30.8% (n=4) and 53.8% (n=7) according to the IEC and ADA 
respectively (see table 3).  
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3 out of 5 subjects in the DM group identified by FPG corresponded in all 3 
categorisations (table 3). One patient has been identified as DM by FPG has 
normal HbA1c, and one was identified as pre-DM, identified by IEC criteria. 2 out 
of 5 patients identified as DM by FPG has been identified as pre-DM by HbA1c 
ADA categorisation. 
The mean metabolic profile is demonstrated in table 4. 
Table 4: Mean Metabolic Profile 
  FPG± SD IEC± SD ADA± SD 
Insulin (5 - 25 
µU/mL) 
Normal 24.40 ± 20.57 25.12 ± 21.25 22.39 ± 18.06 
 Intermediate 
Glycaemia 
29.69 ± 15.90 27.95 ± 16.20 31.25 ± 23.03 
 Diabetes 28.60 ± 29.94 21.29 ± 25.40 21.29 ± 25.40 
Triglyceride 
(mmol/l)+∞ 
Normal 1.59 ± 0.80 1.45 ± 0.60 1.37 ± 0.57 
 Intermediate 
Glycaemia 
2.05 ± 0.87 2.22 ± 1.19 1.97 ± 0.99 
 Diabetes 1.72 ± 1.19 1.89 ± 0.88 1.89 ± 0.88 
Cholesterol 
Ratio∞ 
Normal 4.27 ± 1.35 4.20 ± 1.36 4.01 ± 1.24 
 Intermediate 
Glycaemia 
4.69 ± 1.14 4.57 ± 1.19 4.71 ± 1.40 
 Diabetes 3.72 ± 0.73 4.39 ± 1.00 4.39 ± 1.00 
Uric Acid 
(umol/l) 
Normal 0.38 ± 0.09 0.38 ± 0.09 0.38 ± 0.09 
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 Intermediate 
Glycaemia 
0.36 ± 0.08 0.39 ± 0.08 0.38 ± 0.09 
 Diabetes 0.38 ± 0.07 0.37 ± 0.06 0.37 ± 0.06 
Alanine 
Aminotransfe
rase (u/l) 
Normal 32.76 ± 23.11 32.65 ± 23.33 31.09 ± 22.27 
 Intermediate 
Glycaemia 
29.83 ± 17.13 36.20 ± 21.38 37.13 ± 23.84 
 Diabetes 31.40 ± 9.24 36.86 ± 9.41 36.86 ± 9.41 
Alkaline 
Phosphatase
(u/l) *+∞ 
Normal 79.16 ± 21.76 77.02 ± 21.86 76.36 ± 21.43 
 Intermediate 
Glycaemia 
76.25 ± 25.83 89.65 ± 25.88 84.48 ± 25.07 
 Diabetes 128.20 ± 
65.19 
112.71 ± 
55.20 
112.71 ± 55.20 
Sex 
Hormone-
Binding 
Globulin 
(nmol/l) 
Normal 35.48 ± 24.50 37.02 ± 25.61 38.03 ± 28.38 
 Intermediate 
Glycaemia 
31.10 ± 14.13 25.92 ± 11.92 29.65 ± 12.32 
 Diabetes 33.50 ± 18.36 27.00 ± 11.87 27.00 ± 11.87 
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Testosterone 
(nmol/L) 
Normal 3.07 ± 4.13 2.99 ± 4.12 2.99 ± 4.13 
 Intermediate 
Glycaemia 
1.32 ± 1.90 2.19 ± 3.02 2.58 ± 3.63 
 Diabetes 1.34 ± 0.55 1.60 ± 0.21 1.60 ± 0.21 
* Significance shown in FPG; + significance shown in HbA1c (IEC); ∞ significance shown 
in HbA1c (ADA) with the one-way ANOVA  
 
 
4.2 One Way ANOVA/ Receiver Operating Characteristic (ROC) 
 
One way ANOVA (see tables 5) and ROC curve (see tables 6, 7 and 8) were 
used to compare the differences of metabolic profile between the patients in the 
different groups.  
 
Table 5: ANOVA F-Statistics of Metabolic Profile Identified by FPG, HbA1c IEC 
and ADA Categories (normal glycaemia v IFG/pre-diabetes v DM) 
 
Parameter FPG  
F Value 
HbA1c 
(IEC)         
F Value 
HbA1c 
(ADA)      
F Value 
Insulin  0.457 0.297 2.553 
Triglyceride  1.839 9.242*** 8.151** 
Cholesterol Ratio 1.037 0.679 3.722* 
Uric Acid 0.34 0.215 0.033 
Alanine Aminotransferase 0.098 0.286 1.008 
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Alkaline Phosphatase 9.45*** 7.679*** 6.866** 
Sex Hormone-Binding 
Globulin 
0.211 2.325 2.046 
Testosterone 1.552 0.66 0.437 
*= statistical significant (p<0.05) 
**=highly statistical significant (p<0.01) 
***=very highly statistical significant (p<0.001) 
 
Parametric testing using the one-way ANOVA demonstrated the following (see 
table 5): 
 
 
 
• In subjects identified by FPG, the resulting F statistics in alkaline 
phosphatase was high (F=9.45) and it was found to be very highly 
significant (p <0.001).  
 
• In subjects identified by HbA1c (IEC standard), the resulting F statistics in 
triglyceride and alkaline phosphatase were high (F=9.24 and 7.68) and 
they were found to be very highly significant (p<0.001). 
 
• In subjects identified by HbA1c (ADA standard), the resulting F statistics in 
triglyceride level was high (F=8.15) and it was found to be very highly 
significant (p<0.001); the resulting F statistics in alkaline phosphatase 
(F=6.87) was found to be highly significant (p<0.001) and the resulting F 
statistics in cholesterol level (F=3.722) was found to be significant 
(p=0.027).  
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Table 6: Comparison of Metabolic Profile (Normal vs IFG/pre-diabetes and DM 
combined) Identified by FPG 
Area Under the Curve-FPG 
Test Result 
Variable(s) Area 
Std. 
Errora 
Asymptotic 
Sig.b 
Asymptotic 95% 
Confidence Interval 
Lower 
Bound 
Upper 
Bound 
INSU .625 .076 .102 .476 .773 
TRIG .646 .075 .056 .499 .793 
CHOL .654 .078 .044 .501 .807 
CHR .560 .070 .433 .422 .698 
URIC .453 .069 .536 .317 .589 
ALT .501 .071 .987 .361 .641 
AP .564 .088 .404 .391 .736 
SHBG .448 .078 .498 .295 .601 
TEST .416 .064 .268 .289 .542 
 
 
Table 7: Comparison of Metabolic Profile (Normal vs IFG/pre-diabetes and DM 
combined) Identified by HbA1c (IEC) 
 
Area Under the Curve-HbA1c (IEC) 
Test Result 
Variable(s) Area 
Std. 
Errora 
Asymptotic 
Sig.b 
Asymptotic 95% 
Confidence Interval 
Lower 
Bound 
Upper 
Bound 
INSU .556 .063 .392 .432 .681 
TRIG .704 .063 .002 .580 .828 
CHOL .617 .064 .075 .491 .744 
CHR .582 .060 .215 .464 .699 
URIC .560 .059 .366 .444 .675 
ALT .639 .055 .034 .532 .747 
AP .675 .066 .008 .546 .805 
SHBG .316 .060 .005 .199 .434 
TEST .540 .063 .546 .417 .662 
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Table 8: Comparison of Metabolic Profile (Normal vs IFG/pre-diabetes and DM 
combined) Identified by HbA1c (ADA) 
Area Under the Curve-HbA1c (ADA) 
Test Result 
Variable(s) Area 
Std. 
Errora 
Asymptotic 
Sig.b 
Asymptotic 95% 
Confidence Interval 
Lower 
Bound 
Upper 
Bound 
INSU .641 .053 .012 .538 .744 
TRIG .698 .051 .000 .598 .797 
CHOL .617 .054 .036 .512 .723 
CHR .636 .052 .015 .535 .738 
URIC .512 .055 .829 .405 .620 
ALT .609 .054 .051 .504 .714 
AP .618 .055 .035 .509 .726 
SHBG .415 .054 .129 .309 .522 
TEST .536 .056 .523 .426 .645 
 
 
A non-parametric test, Receiver Operating Characteristic, ROC (see tables 6-8), 
was used to compare the normal (glycaemic/HbA1c) groups with IFG/pre-
diabetes and the DM group. It demonstrated the following:  
• In subjects identified by HbA1c (IEC standard) ROC curves of triglyceride, 
alkaline phosphatase and sex hormone-binding were highly significant 
(p<0.01). In addition, the ROC curve of alanine aminotransferase was 
significant (p=0.034). 
• In subjects identified by HbA1c (ADA standard), the ROC curve of 
triglyceride level are found to be very highly significant (p<0.001), the ROC 
curve of in alkaline phosphatase and cholesterol ratio are found to be 
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significant. The ROC curve of insulin was also shown to be significant 
(p<0.05).  
 
Subjects were separated into male and female and the metabolic profile was re-
analysed. Data were not normally distributed (see Appendix 4: Q-Q Plots), 
therefore ROC was used to analyse data with a non-normal disturbution (see 
table 9-14).  
 
Table 9: Comparison of Metabolic Profile (Normal vs IFG/pre-diabetes and DM 
combined) Identified by FPG (Female) 
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Table 10: Comparison of Metabolic Profile (Normal vs IFG/pre-diabetes and DM 
combined) Identified by FPG (Males) 
 
 
Table 11: Comparison of Metabolic Profile (Normal vs IFG/pre-diabetes and DM 
combined) Identified by HbA1c (IEC) (Female) 
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Table 12: Comparison of Metabolic Profile (Normal vs IFG/pre-diabetes and DM 
combined) Identified by HbA1c (IEC) (Male) 
 
 
 
Table 13: Comparison of Metabolic Profile (Normal vs IFG/pre-diabetes and DM 
combined) Identified by HbA1c (ADA) (Female) 
 
 
 
41 
 
Table 14: Comparison of Metabolic Profile (Normal vs IFG/pre-diabetes and DM 
combined) Identified by HbA1c (ADA) (Male) 
 
 
• In male subjects identified by FPG, ROC curve of triglyceride was 
statistical significant (p <0.05). 
 
• In male subjects identified by HbA1c (IEC standard) ROC curves of 
triglyceride, and alkaline phosphatase were highly significant (p <0.01). In 
addition, the ROC curve of alanine aminotransferase and uric acid was 
significant (p <0.01) and SHBG was very highly significant (p=0.001). 
 
• In female subjects identified by HbA1c (ADA standard), the ROC curve of 
triglyceride level was found to be highly significant (p <0.01); in male 
subjects identified by HbA1c (ADA standard), the ROC curves of 
triglyceride, cholesterol ratio and SHBG level were found to be significant 
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(p <0.05) and the ROC curve of alanine aminotransferase was found to be 
highly significant (p <0.01).  
 
4.3 ATP Criteria for Metabolic Syndrome 
 
The following tables show the number of subjects meeting each of the ATP III 
criteria in the IFG/pre-diabetes group: 
 
Table 15: Patients meeting fasting glucose criterion of ATP III (6.1-6.9 mmol/L) 
 
FPG 
 
 
IEC 
 
ADA 
 
13/13 
 
 
4/21 
 
7/41 
 
 
 
Table 16: Patients meeting triglyceride criterion of ATP III (>1.7 mmol/L) 
 
FPG 
 
 
IEC 
 
ADA 
 
5/13 
 
 
11/21 
 
17/41 
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Table 17: Patients meeting HDL cholesterol criterion of ATP III (<1.04 mmol/L for men, 
<1.30 mmol/L for women) 
 
FPG 
 
 
IEC 
 
ADA 
 
8/13 
 
 
13/21 
 
25/41 
 
 
All of the subjects had BMIs over 35 kg/m2, therefore it was assumed that the 
waist circumference criterion of the ATP III criteria had been met (men: >40 
inches; women: >35 inches). Making this assumption, 10 out of 13 subjects 
(76.92%) met three out of five of the ATP III criteria using FPG; 8 out of 21 
subjects (38.10%) using IEC and 14 out of 41 subjects (34.15%) using the ADA 
criteria in the IFG/pre-diabetes group. Blood pressure data was not transferred 
into the dataset therefore it was not available for the study.  
44 
 
CHAPTER 5  
DISCUSSION 
 
 
Diagnosis of DM is largely based around glycaemia. The advent of glycated 
haemoglobin (HbA1c) measurement in the 1970s provided an additional tool for 
providing more than a ‘snapshot’ of glycaemic control, and has been proven to 
be a reliable monitoring tool for diabetes (Kilpatrick et al., 2009); and it has also 
been shown to be predictive of complications (The DCCT Research Group, 1995, 
Gabbay et al., 1977, UK Prospective Diabetes Study (UKPDS) Group, 1998).  
 
The National Diabetic Data Group in 1979 established the oral glucose tolerance 
test as the preferred diagnostic test for DM (National Diabetes Data Group, 
1979). However, it has poor reproducibility and is a weaker indicator of long-term 
complications compared with other measures of hyperglycaemia (McCance et 
al., 1997). OGTT involves measuring blood glucose values while fasting and at 2 
hours after a 75g oral glucose load is consumed (Scottish Intercollegiate 
Guidelines Network, 2010).  Both OGTT and FPG require fasting. OGTT is 
recommended if casual blood glucose results lie in an uncertain range and if 
fasting glucose results are below those which establish the diagnosis of diabetes 
(Scottish Intercollegiate Guidelines Network, 2010). 
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FPG directly measures the concentration of glucose which contributes to some of 
the complications in DM (The DCCT Research Group, 1995, Gabbay et al., 1977, 
UK Prospective Diabetes Study (UKPDS) Group, 1998). However, the fasting 
requirement can be a challenge for some patients. 
 
In comparison, measurement of HbA1c does not require fasting and is therefore 
a clinically easier test to perform. The DCCT and UKPDS studies showed a 
correlation between HbA1c and macrovascular and microvascular complications. 
HbA1c is an established test for monitoring DM. It has lower within-person 
variability than glucose and it has been considered as a diagnostic test. If specific 
complications of diabetes are caused by chronic hyperglycaemia, long-term 
glycaemic exposure (eg HbA1c) should provide a better marker for the presence 
and severity of DM (The International Expert Committee, 2009). 
 
The potential utility of HbA1c in diabetes was first mentioned in 1985 (World 
Health Organisation, 1985). In 1997, the expert committee on the Diagnosis and 
Classification of Diabetes Mellitus (The International Expert Commitee, 1997) re-
examined the basis of diagnosing DM, based on the relationship between 
glucose and the presence of long-term complications as the basis for the 
diagnosis of DM and they summarised the data negating the widespread 
hypothesis that the OGTT was the gold standard for the diagnosis of DM (IEC 
2009). Based on cross-sectional epidemiological studies of three populations 
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(Egyptian, n=1018; Pima Indians n=960 and NHANES n=2821) (McCance et al., 
1994, Engelgau et al., 1997, The International Expert Committee, 2009), each 
examined glycaemia as FPG, OGTT and HbA1c with retinopathy via fundus 
photography or direct ophthalmoscopy. A clear relationship was found between 
glycaemia and the risk of retinopathy.  The first expert committee on the 
Diagnosis and Classification of Diabetes Mellitus revised the diagnostic criteria, 
using the association between FPG levels and the presence of retinopathy to 
identify the threshold glucose concentration (ADA, 1997). The previous FPG cut-
point of 140mg/dl (7.8mmol/l) was substantially above the glucose concentration 
at which the prevalence of retinopathy begin to increase, therefore the committee 
recommended that the FPG cut-point be decreased to ≥126mg/dl (7.0 mmol/l). 
The new fasting cut-point represents a degree of hyperglycaemia similar to the 
OGTT 2-hour glucose concentration of 11.1 mmol/L and the diagnosis with either 
measure results in a similar prevalence of diabetes in the population (The 
International Expert Committee, 2009).  
 
HbA1c was introduced into clinical use in the 1980s and has become a corner-
stone of clinical practice (Massi-Benedetti, 2006). The 1997 IEC committee 
report showed the prevalence of retinopathy increases substantially at HbA1c 
values starting between 6-7% (American Diabetes Association, 1997). An 
analysis derived from DETECT-2 study and including the previous 3 studies 
mentioned, diabetes specific ‘moderate’ retinopathy was virtually non-existent in 
the >20000 subjects who had HbA1c <6.5% involved in the study (Colagiuri et 
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al., 2011). However, at that point it was recommended against using HbA1c to 
diagnose diabetes due to the difficulties with assay standardisation (American 
Diabetes Association, 1997).  
 
The WHO report in 1999 responded to the ADA recommendations, and the 
diagnostic thresholds of FPG were changed according to their recommendations. 
The standards employed by the WHO are mostly used worldwide. The IEC and 
Diabetes UK also are aligned with these recommendations. 
 
In 2003 follow-up report from the IEC noted that, while the National 
Glycohaemoglobin Standardisation Program had successfully standardised the 
majority of assays in the US (Little et al., 2001), the use of HbA1c was still not 
recommended due to the disadvantages. The WHO 2005 consultation also 
stated that HbA1c should not be used as a diagnostic test, as challenges of 
measurement accuracy outweighed the convenience of its use (World Health 
Organisation, 2006).  
 
In the 2009 report, the IEC endorsed the use of HbA1c test to diagnose diabetes, 
with a threshold of over 6.5%. In selecting a diagnostic level of over 6.5%, the 
IEC balanced the stigma and the cost of mistakenly identifying individuals as 
diabetic, against the minimal clinical consequences of delaying the diagnosis in 
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someone with an HbA1c level of over 6.5% and therefore they have agreed to 
emphasise specificity (ability correctly to identify true negatives, i.e. people 
without diabetes) rather than sensitivity (ability correctly to identify true positives, 
i.e. people with diabetes). This decision was aided by the decision to recommend 
effective prevention strategies for the at-risk group with HbA1c between 6-6.5% 
(The International Expert Committee, 2009). This range should not be an 
absolute threshold at which preventive measures are initiated (Tuomilehto et al., 
2001, Diabetes Prevention Program Research Group, 2002). When assessing 
risk and implementing strategies, other DM risks should be taken into account 
(The International Expert Committee, 2009). The IEC has also stated the FPG 
concentration, rather than the OGTT, is the preferred test to diagnose DM as it is 
more convenient, less costly and time-consuming, and reproducibility of the test 
is superior (The International Expert Committee, 2009). 
 
When recommending the use of HbA1c to diagnose diabetes in the 2009 report 
(The International Expert Committee, 2009), the IEC stressed that those with 
HbA1c above normal (6.0%) but below the diagnostic threshold (6.5%) are at 
high risk of developing diabetes (the incidence of diabetes is increased tenfold in 
this range than when HbA1c is <6.0% (American Diabetes Association, 2010). 
The National Health and Nutrition Examination Survey (NHANES) indicated that 
people with HbA1c 5.5-6% have a 5-year of cumulative incidence of diabetes of 
12-25%. A large prospective study found that a cut-off point of 5.7% has a 
sensitivity of 66% and specificity of 88% in the identification of subsequent 6 year 
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diabetes incidence (Droumaguet C, 2006). The ADA had recommended 
individuals with an HbA1c of 5.7-6.4% should be informed of their increased risk 
for diabetes as well as cardiovascular disease and counselled about effective 
strategies, such as weight loss and physical activity (American Diabetes 
Association, 2010).   
 
When the current study was planned in 2009, HbA1c was routinely used to 
monitor glycaemic control in DM but not for diagnostic purposes. However, the 
WHO 2011 recommendation stated HbA1c can be used as a test in the diagnosis 
of DM, providing that ‘stringent quality assurance tests are in place and assays 
are standardised to criteria aligned to the international reference values’ and 
‘there are no conditions present to preclude its accurate measurement’ (WHO 
2011). An HbA1c of 6.5% is recommended as the cut-off point for the diagnosis 
of diabetes. This was supported by a systematic review (World Health 
Organisation, 2011a) conducted by the Boden Institute of Obesity, Nutrition and 
Exercise, Sydney. The A1c Derived Average Glucose (ADAG) study established 
a validated relationship between HbA1c and average glucose across patient 
populations (Nathan, 2008). An HbA1c of <6.5% does not exclude DM diagnosed 
using glucose tests (WHO 2011) and the consultation concluded that there is 
insufficient evidence to make any formal recommendation on the interpretation of 
HbA1c levels below 6.5% (WHO 2011). 
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A study was conducted to compare diabetes, IFG/pre-diabetes and normal 
glycaemic patients identified by OGTT and the proposed criteria (HbA1c>6.5% 
for diabetes, HbA1c 6-6.4% (IEC) and HbA1c 5.7-6.4% (ADA) for IFG/pre-
diabetes) in three datasets: the Prospective Screening for Impaired Glucose 
Study, the NHANES III and NHANES 2005-2006 (Olson et al., 2010). Using 
OGTT, 5.8% of the combined study subjects had new diabetes, 36% had pre-
diabetes and 58% had normal glucose tolerance. By the IEC criteria, 2.2% of 
patients were classified as having diabetes, 6.2% as high risk and 91.8% had 
normal glucose tolerance; 2.2% were classified as diabetes and 19.3% were high 
risk and 77.8 had normal glucose tolerance by ADA criteria. Evidence has 
revealed both the HbA1c criteria resulted in more normal diagnosis and ADA 
criteria resulted in a distribution of diagnosis more similar to those with OGTT 
criteria, by identifying more patients as high risks and fewer as normal glucose 
tolerance (Olson et al., 2010).  
 
In the current study, we wished to examine a group of patients who are at 
elevated risk of DM on account of their body mass index (BMI). Specifically, we 
wished to establish if the application of these different categorisations identified 
the same subjects in each corresponding group, or different ones. We also 
wished to characterise the metabolic profiles of the patients identified in each 
group, as a secondary outcome. Therefore in this study we have compared the 
number of patients categorised as diabetic/pre-diabetic/normal, and their 
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metabolic characteristics, using the following: (1) FPG (2) HbA1c categorised 
according to IEC criteria: (3) HbA1c categorised according to ADA criteria. 
 
Until June 2009 HbA1c were reported in Diabetes Control and Complication Trial 
(DCCT)-aligned format, with the units being the proportion of the total 
haemoglobin that is glycated expressed as a percentage (Scottish Intercollegiate 
Guidelines Network, 2010). A new standard published by the International 
Federation of Clinical Chemistry and Laboratory Medicine reports results in 
mmol/mol (Barth et al., 2008). In this study the values of HbA1c were written as 
percentages (%), rather than the new unit in milli-moles per mol (mmol/mol). This 
is because many of the specimens were collected prior to the advent of dual 
reporting of old and new units. It was also anticipated that comparisons might be 
drawn with existing (older) studies also reporting HbA1c as percentages. 
 
In our study there were 99 females and 27 male patients, and the female 
preponderance was observed in all groups established by each diagnostic 
system (FPG/HbA1c-IEC/Hb1c-ADA). The patient cohort was recruited 
specifically from a specialist obesity service. The incidence of obesity has been 
reported to be greater in men than women (Kopelman et al., 2010). It is likely that 
women are more likely to seek help regarding to obesity (Hebebrand, 2009) and 
other health problems, therefore they present to their general practitioners and 
are more likely to be referred to the obesity clinic to address the obesity problem. 
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The percentage of patients identified in each group by different categorisations 
are different, with the exception of the diabetes group identified by HbA1c (both 
IEC and ADA standards), as they share the same criteria for DM patient (HbA1c 
>6.4%). The numbers identified as diabetic by each system were small and not 
amenable to statistical analysis. The key difference observed was that more 
patients were identified in the intermediate category by the HbA1c ADA system 
than by either of the other two systems, and correspondingly fewer patients as 
normoglycaemic. More patients have been identified as normoglycaemic by the 
FPG categorisation. 
 
Cross tabulisation was carried out to compare the number of patients identified in 
each group categorised by HbA1c (both IEC and ADA) categorisation and FPG. 
HbA1c (IEC categorisation) agreed more with the FPG categorisation, in relation 
to the number of subjects identified as normal HbA1c/ normal glycaemia. This is 
likely due to a lower threshold the ADA classification has for pre-DM (5.7% as to 
6.0%). Therefore, some subjects were categorised as pre-diabetic by the ADA 
criterion but as normoglycaemic by other diagnostic systems. Subjects could be 
identified as intermediate glycaemia but with a normal HbA1c.  
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Ethnic differences could not be demonstrated, as most patients in our cohort 
were Caucasian. Caution is advised in interpretation of these results due to the 
small sample size. 
 
Metabolic syndrome is a complex disorder defined by factors, which increase the 
risk of cardiovascular atherosclerotic diseases and diabetes mellitus type 2. It 
was described by Reaven (1998) as Syndrome X. He noted that several risk 
factors, e.g. dyslipidemia, hypertension, hyperglycaemia, are clustered together; 
and he postulated that insulin resistance was the underlying factor associated 
with diabetes and coronary heart disease (Reaven, 1988). Different 
organisations, for example, the WHO and the American Association of Clinical 
Endocrinologists, proposed different clinical criteria for metabolic syndrome 
(Grundy 2004, WHO 1998, AACE). The National Cholesterol Education 
Program’s Adult treatment Panel III report (ATP III) identified cardiovascular 
disease as the primary clinical outcome of metabolic syndrome; most people with 
metabolic syndrome have insulin resistance and increased risks of diabetes. The 
ATP III identified 6 components of the metabolic syndrome:  
 
1. Abdominal obesity 
2. Atherogenic dyslipidemia 
3. Hypertension 
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4. Insulin resistance +/- glucose intolerance 
5. Proinflammatory state 
6. Prothrombotic state 
 
The pathogenesis of metabolic syndrome involves:  
• Obesity and abnormal body fat distribution: abdominal obesity especially 
correlates with metabolic risk factors. Products released by adipose tissue 
including non-esterified fatty acids (NEFA), cytokines, plasminogen 
activator inhibitor-1 (PAI-1) and adiponectin, cause insulin resistance, a 
proinflammatory and prothrombotic state and worsening metabolic risk 
factors. The strong connection between obesity and these risk factors 
defined metabolic syndrome as a clustering of metabolic complications of 
obesity (Grundy et al., 2004). 
• Insulin resistance-fatty liver and atherogeneic dyslipidaemia can be 
caused by insulin resistance: enhanced release of NEFA from insulin-
resistant adipose tissue leads to a liver overloaded with lipids, leading in 
turn to increase hepatic output of very-low-density lipoprotein particles 
carrying predominantly triglycerides. Insulin resistance in muscles 
predisposes glucose intolerance, worsened by increased hepatic 
gluconeogenesis in insulin-resistant liver (Grundy et al., 2004). 
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• Independent and other contributing factors including genetic and other 
acquired factors, advanced age and endocrine factors. These factors can 
affect lipoprotein metabolism, blood pressure regulation, body fat 
distribution and pathogenesis (Grundy et al., 2004). 
 
Using one way-ANOVA, we compared the metabolic profiles of patients 
categorised according to each of the three diagnostic tests. The metabolic profile 
included insulin, cholesterol ratio, triglyceride, uric acid, androgen status (sex-
hormone binding globulin (SHBG) and testosterone), and liver function tests 
(including alanine aminotransaminase and alkaline phosphatase). Differences 
were observed in some of the metabolic profiles of patients identified by different 
diagnostic systems. A high F value and a very highly statistical significance in 
alkaline phosphatase of patients identified by all the different categorisations was 
demonstrated by FPG categorisation; this could be due to patients with impaired 
fasting glycaemia and diabetes having higher alkaline phosphatase reflecting 
fatty liver. Normality of the entire data was not assessed. Differences in alkaline 
phosphatase and triglyceride were demonstrated in patients identified by HbA1c 
(IEC) and this finding was also corroborated using the ROC test.  
 
As anticipated, mean triglycerides and total/HDL cholesterol ratios were higher in 
the IFG/pre-diabetes and diabetes groups identified by all diagnostic systems, 
comparing to normoglycaemic patients. This probably reflects metabolic 
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syndrome, which is known to be associated with hyperglycaemia, 
hyperinsulinaemia and hypertriglyceridaemia. Most people with obesity have 
relatively low insulin sensitivity (Bogardus et al., 1985), but there is variation in 
insulin sensitivity within the obese population (Abbasi et al., 2002). Certain 
metabolic characteristics are expected from obese patients, for examples, high 
insulin, decreased testosterones in males, increased testosterones in females 
and decreased SHBG (Pasquali, 2006). 
 
Statistical significant in F-statistics were observed more frequently in the 
measured metabolic profile of patients identified by HbA1c (ADA) category (e.g. 
alkaline phosphatase, p=0.02; triglycerides p<0.001 and cholesterol ratio 
p=0.027). This probably reflects the wider pre-diabetic range of HbA1c (ADA).  
 
After analysing the data with the male and female sex separately, it was found 
that the data was not evenly distributed; ROC was therefore used to analyse the 
metabolic data. There were no differences illustrated in the metabolic profile of 
female subjects except triglyceride in the ADA group. This probably reflects the 
wider pre-diabetic range of HbA1c (ADA). There were significant differences in 
triglycerides across the male groups in each categorisation (FPG, HbA1c IEC 
and ADA). Differences were also demonstrated in uric acid, alanine 
aminotransferase, alkaline phosphatase and SHBG in the male subjects in the 
male subjects of the HbA1c (IEC) categorisation; and cholesterol ratio, alanine 
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aminotransferase and SHBG in the male subjects of the HbA1c (ADA) 
categorisation.  The differences might be due to the very small sample number of 
the male group after the splitting of the subjects into male and female. These 
results are to be interpreted with caution as the small number may mean the 
results are not representative. 
 
This patient cohort was chosen for this study, since it is considered that obesity is 
associated with DM and metabolic syndrome. 59 out of the original 212 patients 
(27.8%) were excluded for this study due to existing DM and were on oral anti-
hyperglycaemic agents, which reflected the high prevalence of diabetes in this 
particular patient cohort.  
 
Patients who were identified with diabetes by HbA1c might have had been 
identified with IFG, or normal glycaemic by FPG test and therefore are false 
positives. This data is to be interpreted with caution due to the small sample size 
and the BMI results can be incidental.  
 
Additional tests were carried out to establish any differences in the number of 
patients identified by FPG, HbA1c (IEC and ADA criteria) matching the ATP III 
criteria. While the blood pressure information was not available, all the patients in 
the groups were already assumed to have abdominal obesity due to the high BMI 
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(Lean et al., 1995). FPG identified more patients with higher fasting glucose, in 
the IFG/pre-diabetes category, compared to patients identified with the HbA1c 
categorisation. Patients who met the HDL criterion were similar in the IFG/pre-
diabetes category. This could be due to obese patients having lower HDL. The 
differences in the number of patients with different fasting glucose and 
triglyceride levels might have contributed to the differences in the FPG and the 
HbA1c (both ADA and IEC) tests meeting the ATP III criteria for metabolic 
syndrome.   
 
There are strengths of this study: the cohort of patients was recruited from a very 
similar background: the weight management specialist service in a single centre. 
The population from this cohort were similar, which means there were less 
discrepancies and variations in the patient’s demographic and metabolic profile. 
Patients’ age, BMI and race were similar, therefore fewer discrepancies were 
caused by these possible influencing factors. These patients live in a similar 
geographical area in Tayside and therefore the patients’ data is less affected by 
environmental factors. As discussed earlier, one of the disadvantages of the 
HbA1c test is the variations in different laboratories. Because this is a single 
centre study, all the blood samples from biochemistry were dealt with by a single 
laboratory therefore the variations are limited and the results are more 
consistent.  
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The challenge of this study was that although the study was initially planned as a 
prospective study, some data had to be gathered retrospectively. Some of the 
data were missing (eg some of the FPG, HbA1c and metabolic profile 
measurements) therefore they were unavailable for analysis. Also, the 
retrospective study replied on others for accurate record-keeping eg the BMI 
data, which may vary from clinic to clinic. 
 
When planning the project, past medical history and medication were not 
considered therefore these data were not collected. Some medications eg anti-
hypertensives and statins, might have effects on the metabolic profiles (eg lipids) 
that affect the results of the study. As medication data were not collected, some 
of the diabetic subjects excluded for the study might not have been on glucose-
lowering therapy therefore the number for diabetic patients could have been 
greater. Exclusion of the 59 subjects may mean metabolic data for the diabetic 
group of subject is lost, which may have been valuable for analysis. 
 
When the metabolic profile data was first analyse as a whole set (ie with male 
and female subject merged in), the normality of the data was not analysed. Both 
ANOVA and ROC approach were used to analyse the data, to cover the data 
distribution, whether it is parametric or not.  This can lead to interpreting the data 
incorrectly although some results did correlate. Some hormones, for examples, 
SHBG and testosterone, the levels vary between male and female. Without 
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separating the results into male and female, the analysis of this data would not 
be useful. 
 
 After separating the subjects into male and female for re-analysis of the 
metabolic data, some of the groups have small subject number (eg male subjects 
in IFG/pre-diabetes groups) and others have no male subjects in the diabetes 
group in both HbA1c (IEC and ADA) categorisations, leading to small samples for 
analyses and thus potentially inaccurate results. 
 
Other weaknesses of the project were as follows: the comparison of the patient’s 
group identified by FPG/ HbA1c (IFG and ADA criteria) with the ATP III criteria 
was a post hoc analysis (conceived after the initiation of the project; i.e. the data 
were not collected specifically for this analysis and therefore not all the data was 
available for this purpose. Blood pressure of the patients was not recorded into 
the database and therefore could not be used as a criterion for comparison. 
Waist circumference was not available in the database, however, since all the 
subjects had BMI greater than 35kg/m2 it was estimated that this criterion was 
met (Lean et al., 1995). 
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CHAPTER 6 
CONCLUSION 
 
 
In our study, HbA1c (ADA) criteria predictably identified more people at risk of 
developing diabetes than HbA1c (IEC) criteria, on account of a lower HbA1c cut-
off (5.7% versus 6.0%). It also identified more people in the pre-diabetes 
category than IFG were identified by FPG. In both the pre-diabetes groups 
identified by the HbA1c IEC and ADA criteria, the fasting glucose values are 
lower than the IFG category in the FPG test. The implication of this is that some 
people are identified as having pre-diabetes by HbA1c-based criteria, who do not 
have IFG. It may mean that these patients are more at risk of developing DM in 
the future therefore follow-ups are required. However, it could also mean that 
these patients could be falsely identified as pre-diabetes, or a category of 
‘patients in higher risks of developing DM’.  Labeling patients as pre-diabetes, or 
indicating that they have higher risks in developing DM, may have implications in 
their daily living such as employment and insurance. The diagnostic tests, FPG 
or HbA1c, have to be interpreted in context with individual basis, along with risk 
factors an individual may have, in terms of developing DM. 
 
The ANOVA test of the metabolic profile showed significant F statistics in 
triglyceride was also identified in HbA1c (both IEC and ADA standards) and 
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cholesterol ratio in the HbA1c (ADA) diagnostic test. A wider range of HbA1c in 
the pre-diabetes group may mean a different distribution of patients therefore the 
more varied metabolic profile results within and between the groups. The 
significance of the ROC curves in the male groups after separating the metabolic 
profile into female and male sexes might not be relevant, due to the small 
number of subjects. 
 
There were also differences detected in the number of patients identified with 
IFG/pre-diabetes by all three different diagnostic systems (FPG, HbA1c IEC and 
ADA criteria) who met three of the ATP III criteria for metabolic syndrome. This 
was likely due to the lower fasting glucose observed in patients identified by 
HbA1c-based systems. FPG measures the molecules that directly measure 
glycaemia, while HbA1c measures glycated haemogloblin, which reflects chronic 
glycaemia and it does not measure the glucose molecules directly, but rather the 
relation between glycaemia and Hb glycation.  
 
It is thus possible to have discrepancies identifying IFG and pre-diabetes using 
different classifications e.g. FPG and HbA1c, therefore explaining the lower 
fasting glucose in the HbA1c intermediate groups than the IFG group identified 
by FPG. Obesity correlates with metabolic risk factors therefore the reason these 
patients have similar metabolic profiles could be due to the pathophysiology in 
obesity. 
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This research project provided a small scale study to compare HbA1c with FPG 
in the diagnosis of type 2 diabetes and intermediate hyperglycaemia (impaired 
fasting glycaemia), in our specific cohort of patients. This study was limited by 
small sample size, after the exclusion of patients with existing DM and patients 
with non-fasting blood samples. These tests should be repeated on a larger 
sample size to ensure the stability of the results, and also the possibility of multi-
centre studies.  It is recommended that a medium to long-term follow-up of these 
patients is conducted in order to observe the development of diabetes from the 
IFG/pre-diabetes group identified by all three tests (FPG, HbA1c IEC and ADA 
criteria).  
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APPENDIX 1: FREQUENCY TABLE 
Frequency Table 
FBG_group 
  Frequency Percent Valid Percent Cumulative Percent 
Valid Normal0 102 81.0 85.0 85.0 
Intermed Glycemia1 13 10.3 10.8 95.8 
Diabetes2 5 4.0 4.2 100.0 
Total 120 95.2 100.0   
Missing System 6 4.8     
Total 126 100.0     
HbA1c_IEC_Group 
  Frequency Percent Valid Percent Cumulative Percent 
Valid Normal0 89 70.6 76.1 76.1 
Intermed Glycemia1 21 16.7 17.9 94.0 
Diabetes2 7 5.6 6.0 100.0 
Total 117 92.9 100.0   
Missing System 9 7.1     
Total 126 100.0     
HbA1b_ADA_Group 
  Frequency Percent Valid Percent Cumulative Percent 
Valid Normal0 69 54.8 59.0 59.0 
Intermed Glycemia1 41 32.5 35.0 94.0 
Diabetes2 7 5.6 6.0 100.0 
Total 117 92.9 100.0   
Missing System 9 7.1     
Total 126 100.0     
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APPENDIX 2: ANOVA 
 
ANOVA-FPG 
  Sum of Squares df Mean Square F Sig. 
INSU Between Groups 385.150 2 192.575 .457 .635 
Within Groups 48934.128 116 421.846     
Total 49319.277 118       
TRIG Between Groups 2.481 2 1.240 1.839 .164 
Within Groups 78.914 117 .674     
Total 81.395 119       
CHOL Between Groups 5.997 2 2.999 2.827 .063 
Within Groups 123.038 116 1.061     
Total 129.035 118       
CHR Between Groups 3.591 2 1.796 1.037 .358 
Within Groups 200.860 116 1.732     
Total 204.452 118       
URIC Between Groups 
.005 2 .003 .340 .712 
Within Groups 
.928 117 .008     
Total 
.934 119       
ALT Between Groups 97.604 2 48.802 .098 .906 
Within Groups 57509.220 116 495.769     
Total 57606.824 118       
AP Between Groups 11755.779 2 5877.890 9.450 .000 
Within Groups 72154.540 116 622.022     
Total 83910.319 118       
SHBG Between Groups 231.814 2 115.907 .211 .810 
Within Groups 64374.961 117 550.213     
Total 64606.775 119       
TEST Between Groups 46.619 2 23.310 1.552 .216 
Within Groups 1712.210 114 15.019     
Total 1758.829 116       
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ANOVA-HbA1c (IEC) 
  Sum of Squares df Mean Square F Sig. 
INSU Between Groups 255.291 2 127.646 .297 .744 
Within Groups 48588.019 113 429.982     
Total 48843.310 115       
TRIG Between Groups 10.515 2 5.257 9.242 .000 
Within Groups 64.853 114 .569     
Total 75.368 116       
CHOL Between Groups 6.362 2 3.181 3.050 .051 
Within Groups 117.851 113 1.043     
Total 124.214 115       
CHR Between Groups 2.357 2 1.179 .679 .509 
Within Groups 196.170 113 1.736     
Total 198.527 115       
URIC Between Groups 
.003 2 .002 .215 .807 
Within Groups 
.911 114 .008     
Total 
.915 116       
ALT Between Groups 288.706 2 144.353 .286 .752 
Within Groups 57128.259 113 505.560     
Total 57416.966 115       
AP Between Groups 9930.575 2 4965.287 7.679 .001 
Within Groups 73065.934 113 646.601     
Total 82996.509 115       
SHBG Between Groups 2504.056 2 1252.028 2.325 .102 
Within Groups 61386.873 114 538.481     
Total 63890.929 116       
TEST Between Groups 19.552 2 9.776 .660 .519 
Within Groups 1643.862 111 14.810     
Total 1663.414 113       
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ANOVA-HbA1c (ADA) 
  Sum of Squares df Mean Square F Sig. 
INSU Between Groups 2111.947 2 1055.973 2.553 .082 
Within Groups 46731.363 113 413.552     
Total 48843.310 115       
TRIG Between Groups 9.430 2 4.715 8.151 .000 
Within Groups 65.938 114 .578     
Total 75.368 116       
CHOL Between Groups 7.551 2 3.776 3.657 .029 
Within Groups 116.662 113 1.032     
Total 124.214 115       
CHR Between Groups 12.269 2 6.134 3.722 .027 
Within Groups 186.258 113 1.648     
Total 198.527 115       
URIC Between Groups 
.001 2 .000 .033 .967 
Within Groups 
.914 114 .008     
Total 
.915 116       
ALT Between Groups 1006.255 2 503.128 1.008 .368 
Within Groups 56410.710 113 499.210     
Total 57416.966 115       
AP Between Groups 8993.163 2 4496.582 6.866 .002 
Within Groups 74003.346 113 654.897     
Total 82996.509 115       
SHBG Between Groups 2214.319 2 1107.159 2.046 .134 
Within Groups 61676.611 114 541.023     
Total 63890.929 116       
TEST Between Groups 13.004 2 6.502 .437 .647 
Within Groups 1650.411 111 14.869     
Total 1663.414 113       
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APPENDIX 3: ROC 
 
Area Under the Curve-FPG 
Test Result Variable(s) Area Std. Errora Asymptotic Sig.b 
Asymptotic 95% Confidence Interval 
Lower Bound Upper Bound 
INSU 
.625 .076 .102 .476 .773 
TRIG 
.646 .075 .056 .499 .793 
CHOL 
.654 .078 .044 .501 .807 
CHR 
.560 .070 .433 .422 .698 
URIC 
.453 .069 .536 .317 .589 
ALT 
.501 .071 .987 .361 .641 
AP 
.564 .088 .404 .391 .736 
SHBG 
.448 .078 .498 .295 .601 
TEST 
.416 .064 .268 .289 .542 
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Area Under the Curve-HbA1c (IEC) 
 
Test Result Variable(s) Area Std. Errora Asymptotic Sig.b 
Asymptotic 95% Confidence 
Interval 
Lower Bound Upper Bound 
INSU 
.556 .063 .392 .432 .681 
TRIG 
.704 .063 .002 .580 .828 
CHOL 
.617 .064 .075 .491 .744 
CHR 
.582 .060 .215 .464 .699 
URIC 
.560 .059 .366 .444 .675 
ALT 
.639 .055 .034 .532 .747 
AP 
.675 .066 .008 .546 .805 
SHBG 
.316 .060 .005 .199 .434 
TEST 
.540 .063 .546 .417 .662 
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Area Under the Curve-HbA1c (ADA) 
Test Result Variable(s) Area Std. Errora Asymptotic Sig.b 
Asymptotic 95% Confidence Interval 
Lower Bound Upper Bound 
INSU 
.641 .053 .012 .538 .744 
TRIG 
.698 .051 .000 .598 .797 
CHOL 
.617 .054 .036 .512 .723 
CHR 
.636 .052 .015 .535 .738 
URIC 
.512 .055 .829 .405 .620 
ALT 
.609 .054 .051 .504 .714 
AP 
.618 .055 .035 .509 .726 
SHBG 
.415 .054 .129 .309 .522 
TEST 
.536 .056 .523 .426 .645 
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APPENDIX 4: Q-Q PLOT FOR NORMALITY 
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APPENDIX 5: ROC (Female and Male) 
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